PPH - Eli Lilly Novo among notable decliners in pharma weakness
2023-10-19 11:39:51 ET
More on AbbVie, Eli Lilly, etc.
- AbbVie: The Humira Loss May Be Fully Priced In After All
- AbbVie: Q2 Success Sets The Stage For Consistent Growth
- AbbVie: Why You Should Pay Attention To This High-Yielding Dividend King (Rating Downgrade)
- GE HealthCare, Novo Nordisk to advance ultrasound-based obesity therapy
- Eli Lilly to buy cancer drug developer Mablink (updated)
For further details see:
Eli Lilly, Novo among notable decliners in pharma weakness